Repligen Co. (NASDAQ:RGEN) Holdings Decreased by Quadrant Capital Group LLC

Quadrant Capital Group LLC reduced its holdings in Repligen Co. (NASDAQ:RGEN) by 21.6% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 377 shares of the biotechnology company’s stock after selling 104 shares during the period. Quadrant Capital Group LLC’s holdings in Repligen were worth $54,000 at the end of the most recent reporting period.

Other institutional investors have also recently bought and sold shares of the company. Ballentine Partners LLC grew its holdings in shares of Repligen by 4.0% during the 4th quarter. Ballentine Partners LLC now owns 1,879 shares of the biotechnology company’s stock valued at $270,000 after acquiring an additional 72 shares in the last quarter. CIBC Asset Management Inc boosted its position in Repligen by 5.0% during the fourth quarter. CIBC Asset Management Inc now owns 1,706 shares of the biotechnology company’s stock valued at $246,000 after purchasing an additional 81 shares during the last quarter. MML Investors Services LLC grew its stake in Repligen by 2.7% in the third quarter. MML Investors Services LLC now owns 3,383 shares of the biotechnology company’s stock valued at $503,000 after purchasing an additional 89 shares in the last quarter. GAMMA Investing LLC increased its position in Repligen by 15.2% in the 4th quarter. GAMMA Investing LLC now owns 684 shares of the biotechnology company’s stock worth $98,000 after purchasing an additional 90 shares during the last quarter. Finally, Louisiana State Employees Retirement System raised its stake in shares of Repligen by 0.7% during the 4th quarter. Louisiana State Employees Retirement System now owns 14,500 shares of the biotechnology company’s stock worth $2,087,000 after purchasing an additional 100 shares in the last quarter. 97.64% of the stock is currently owned by institutional investors and hedge funds.

Insiders Place Their Bets

In other news, Director Margaret Pax acquired 250 shares of the stock in a transaction dated Monday, March 17th. The shares were acquired at an average cost of $150.69 per share, for a total transaction of $37,672.50. Following the completion of the transaction, the director now owns 1,043 shares in the company, valued at approximately $157,169.67. This trade represents a 31.53 % increase in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Company insiders own 1.20% of the company’s stock.

Repligen Price Performance

Shares of NASDAQ:RGEN opened at $122.86 on Friday. The company has a quick ratio of 8.76, a current ratio of 10.44 and a debt-to-equity ratio of 0.26. The business has a 50 day moving average price of $143.12 and a 200 day moving average price of $146.32. The company has a market cap of $6.90 billion, a price-to-earnings ratio of -240.90, a PEG ratio of 4.54 and a beta of 1.27. Repligen Co. has a twelve month low of $102.97 and a twelve month high of $182.52.

Repligen (NASDAQ:RGEN) last posted its quarterly earnings data on Thursday, February 20th. The biotechnology company reported $0.44 earnings per share for the quarter, beating the consensus estimate of $0.41 by $0.03. Repligen had a positive return on equity of 4.21% and a negative net margin of 4.64%. The company had revenue of $167.55 million during the quarter, compared to analysts’ expectations of $167.58 million. Research analysts predict that Repligen Co. will post 1.72 earnings per share for the current year.

Analyst Ratings Changes

A number of equities analysts recently commented on RGEN shares. HC Wainwright restated a “buy” rating and issued a $180.00 price objective on shares of Repligen in a report on Friday, February 21st. Evercore ISI started coverage on shares of Repligen in a research note on Tuesday, March 18th. They set an “in-line” rating and a $155.00 price target on the stock. Canaccord Genuity Group raised their price target on shares of Repligen from $165.00 to $170.00 and gave the company a “hold” rating in a report on Friday, February 21st. Canaccord Genuity Group initiated coverage on shares of Repligen in a report on Tuesday, December 17th. They issued a “hold” rating and a $165.00 price objective for the company. Finally, StockNews.com upgraded Repligen from a “sell” rating to a “hold” rating in a report on Friday, April 4th. Seven analysts have rated the stock with a hold rating and eight have given a buy rating to the company. Based on data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average target price of $178.64.

Repligen Profile

Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products.